Procrit Market 2026 growth is driven by the rising prevalence of anemia.

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Procrit Market At The End Of The 2026–2030 Forecast Period?

The expansion observed throughout the historical era was driven by several contributing factors, such as the growing occurrence of chronic kidney disease, an uptick in instances of chemotherapy-related anemia, the embrace of biologic treatments for anemia, the proliferation of dialysis facilities, and better accessibility to prescribed medications for anemia.

Future growth is expected to stem from a heightened emphasis on individualized anemia care, increased uptake of biosimilar options, the broadening of chronic illness treatment initiatives, a stronger focus on enhancing patients’ quality of life, and greater funding directed towards optimizing biologic medications. Key developments anticipated during the forecast period encompass a surge in the application of erythropoiesis-stimulating agents, a heightened need for treatments managing anemia, the extension of supportive care for oncology patients, an intensified drive to minimize blood transfusions, and improved oversight of ongoing anemia conditions.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20189&type=smp

Which Market Drivers Are Supporting The Expansion Of The Procrit Market?

The rising prevalence of anemia is anticipated to boost the Procrit market in the coming years. Anemia is identified as a medical condition where there is an insufficient amount of healthy red blood cells or hemoglobin, leading to inadequate oxygen supply to the body’s tissues. The increase in anemia cases stems from factors such as the growing global incidence of chronic conditions like kidney failure, cancer, and inflammatory disorders, alongside insufficient nutrition causing deficiencies in essential nutrients such as iron, vitamin B12, and folate. Procrit (epoetin alfa) serves as a treatment for anemia resulting from chronic kidney disease, chemotherapy, or specific HIV therapies. Its mechanism involves encouraging the creation of red blood cells, thereby decreasing the necessity for blood transfusions in individuals with low hemoglobin concentrations. As an illustration, data from the National Center for Health Statistics, a US government agency, indicated in December 2024 that the occurrence of anemia in individuals aged 2 years and older saw a 9.3% rise in 2023 compared to 2021. Consequently, the increasing prevalence of anemia is a key factor propelling the Procrit market. The growing incidence of chronic kidney diseases is anticipated to drive the Procrit market in the future. Chronic kidney disease describes a state where the kidneys progressively diminish their capacity to purify waste from the bloodstream. The increase in chronic kidney disease cases can be attributed to an aging global demographic, growing rates of obesity, and various lifestyle factors combined with environmental influences. Procrit (epoetin alfa) is administered to individuals with chronic kidney disease to manage anemia by stimulating the generation of red blood cells, which aids in sustaining appropriate hemoglobin levels and lessening the necessity for blood transfusions. For example, a report released by Kidney Research UK, a UK non-profit, in June 2023 indicated that roughly 7.2 million people in the UK are presently afflicted with chronic kidney disease, accounting for more than 10% of the population. Among these, 3.25 million are in advanced stages, with another 3.9 million in early stages. Projections suggest that by 2033, the count of those impacted by chronic kidney disease will increase to 7.61 million. Consequently, the escalating prevalence of chronic kidney diseases serves as a significant impetus for the Procrit market.

What Segment Types Make Up The Procrit Market?

The procrit market covered in this report is segmented –

1) By Indications: Chronic Kidney Diseases, Human Immunodeficiency Virus (HIV) Infection, Chemotherapy

2) By Distribution Channel: Direct Sales, Pharmaceutical Wholesalers, Retail Pharmacies

3) By End Users: Hospitals, Outpatient Clinics, Home Care

Who Are The Key Players Driving Competition In The Procrit Market?

Major companies operating in the procrit market are Amgen Inc.

Read the full procrit market report here:

https://www.thebusinessresearchcompany.com/report/procrit-global-market-report

How Is The Procrit Market Distributed Across Key Geographic Regions?

North America was the largest region in the procrit market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the procrit market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Procrit Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20189&type=smp

Browse Through More Reports Similar to the Global Procrit Market 2026, By The Business Research Company

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795